With a mission to accelerate scientific discovery and develop new generations of cell therapies, bit. bio offers a wide range of products and services. Using their patented gene-targeting approach, opti-ox™, they can reprogram human induced pluripotent stem cells (iPSCs) into mature and highly defined human cell types.

These cells, marketed under the ioCells brand, include nerve cells, immune cells, and muscle cells, among others. In addition to their cell products, bit. bio also provides disease models for research and drug discovery.

Founded in 2016 as a spin-off from the University of Cambridge, bit. bio has quickly gained recognition in the industry. They have raised $150 million in capital from notable investors such as Arch Ventures and Tencent.

Led by a team of experts in synthetic biology, stem cells, and manufacturing, bit. bio is on the cutting edge of scientific innovation. Their board includes renowned figures like Dr.

Hermann Hauser and Nobel laureate Sir Gregory Winter. With their commitment to coding cells for novel cures, bit. bio is transforming the way we approach biomedical research and paving the way for breakthrough therapies